Welcome to Beacon Equity Research. Today is Thursday, 3 January 2008  
 Home   Covered Companies   News and Commentary   TraderNotes   Our Team   Ratings   Contact Us   Charity   Affiliates  
 
Commentary

Wal-Mex - A growing behemoth from the South

Wal-Mart subsidiary offers double-digit net income growth

Ever wonder what your life would be like today if you or your parents had possessed the foresight to invest in Wal-Mart (NYSE: WMT) back when it was just a young, upstart company from Northwest Arkansas?



Read also:
>  Trimming the Fat - Dynacq Healthcare Inc. (DYII) hoping to help thwart China's obesity crisis
>  Synthetic Blood International (SYBD) is set to capitalize on strong blood substitutes market
>  Open Energy Corporation (OEGY) could benefit from $3.2 billion California Solar Initiative
>  Cell Genesys searches for a cure to prostate cancer
>  RemoteMDx, Inc. (RMDX) Strengthened by Monitoring Center Upgrade

Read more in News and Commentary







Skinvisible, Inc. (SKVI) Enters Into Marketing Agreement with Avani International for India

According to IMS Health’s 2008 Global Pharmaceutical Market and Therapy  Forecast, the global pharmaceutical market is expected to grow at a 5-6% pace next year, compared with 6-7% in 2007.  The forecast predicts global pharmaceutical sales to expand to US$735 - 745 billion next year.  The seven “pharmerging” markets of China, Brazil, Mexico, South Korea, India, Turkey and Russia are expected to grow 12 - 13 % next year, to $85 - 90 billion.  Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., develops innovative polymer delivery vehicles and related compositions which when topically applied hold active ingredients on the skin for up to four hours thereby affording the active agent an extended timeframe to perform its intended function.  The Company also produces a variety of products that incorporate its technology for private label clients, including antimicrobial hand sanitizers, sunless tanning sprays, sunscreens and skincare products.

 

Skinvisible Pharmaceutical's primary objective is to license its patented technology and sell its trademarked polymer delivery vehicles to established brand manufacturers and marketers of prescription and over-the-counter ("OTC") products in the dermatological, medical, cosmetic, and skincare markets.  Skinvisible Inc. (SKVI) recently announced that it has signed a marketing agreement with Avani International for India. This follows Skinvisible's recent announcement that it was granted a comprehensive patent in India for Skinvisible's proprietary polymer delivery system, Invisicare.  Invisicare enhances the delivery of topical dermatology products on the skin.

 

The agreement with Avani is part of Skinvisible's continued strategy to quickly expand its reach around the globe.  Avani will seek licenses in India for topical products Skinvisible has developed for the treatment of acne, fungal infections, atopic dermatitis and hand sanitizers. They will also facilitate clinical studies and manufacturing in India.  

As stated by Terry Howlett, President and CEO of Skinvisible, Inc., "It is important for Skinvisible to develop partnerships with companies such as Avani as they have established relationships with pharmaceutical and consumer goods companies in India. This helps us fast track our marketing efforts in the country and generate license fees and royalties quicker than marketing in India ourselves."

Ash Chawla, Chairman & CEO of Avani commented, "India and its expanding population of over 1 billion people offers tremendous market opportunities for Skinvisible and its Invisicare technology and products.  This agreement allows us to introduce Invisicare to Indian pharmaceutical manufacturers that we know need this technology."

 

About Skinvisible, Inc. (SKVI)

Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., develops innovative polymer delivery vehicles and related compositions which when topically applied hold active ingredients on the skin for up to four hours thereby affording the active agent an extended timeframe to perform its intended function. Aligned with its research and development focus, Skinvisible's primary objective is to license its patented technology and sell its trademarked polymer delivery vehicles to established brand manufacturers and marketers of prescription and over-the-counter ("OTC") products in the dermatological, medical, cosmetic, and skincare markets. The Company also produces a variety of products that incorporate its technology for private label clients, including antimicrobial hand sanitizers, sunless tanning sprays, sunscreens and skincare products.
 
< Prev   Next >

 
Copyright 2007 Beacon Equity Research